载脂蛋白M单克隆抗体的制备及其初步应用

目的 制备亲和力高、纯度好的载脂蛋白M(apoM)单克隆抗体,并用以检测apoM在组织细胞及不同人群中的分布.方法 用重组apoM蛋白免疫Balb/c小鼠,经细胞融合、筛选及克隆化,得到生长良好、分泌稳定的杂交瘤细胞株;注射Balb/c小鼠腹腔,收取腹腔积液,纯化后得到apoM单克隆抗体,并用本实验制备的单克隆抗体检测健康对照组及冠状动脉粥样硬化性心脏病(冠心病)患者稳定型心绞痛(sA)组和急性冠状动脉综合征(ACS)组血清中的apoM蛋白浓度.结果 得到了3株单克隆抗体,经亚型鉴定、阻断试验和WB确定为apoM单克隆抗体;并通过该抗体在人细胞和组织中检测到了apoM蛋白.冠心病SA组的apoM浓度为(11.02±1.96)×10-3 g/L,ACS组apoM浓度为(10.76±1.32)×10-3g /L,对照组为(12.83±2.28)×10-3 g/L,3组间差异有统计学意义(F=11.544,P＜0.05).比较冠心病sA组和ACS组与健康对照组血浆apoM浓度,显示两组冠心病患者血浆apoM浓度均低于健康对照组(t=2.962、3.967,P＜0.05),两组冠心病组之间血浆apoM浓度差异无统计学意义(t=1.033,P＞0.05).结论 成功制备了3株apoM的单克隆抗体,可与人组织细胞中的apoM蛋白特异结合,为进一步研究apoM在脂代谢中的作用打下了基础.     

载脂蛋白M单克隆抗体的制备及其初步应用

Objective To prepare anti-apoM monoantibodies with high affinity and high purity, and investigate apoM distribution among human tissues and different groups of people. Methods BALB/c mice were injected intracutaneously with recombinant apoM. After cytomixis, screening and cloning, we established a hybridoma, which grew well and steadily secreted antibodies. The ascites were acquired by injecting BALB/c mice intraperitoneally and anti-apoM monoantibodies were gained using standard techniques. We detected apoM levels in healthy individuals and the patients with coronary heart disease including stable angina (SA) group and acute coronary syndrome (ACS) group using the anti-apoM monoantibodies. ResultsThree anti-apoM monoantibodies were collected and confirmed after subtype identification and block test. The apoM protein were detected in some human cells and human tissues by these three monoantibodies. The concentration of apoM was (11.02 ±1.96) ×10 -3 g/L, (10. 76± 1.32) ×10-3 g/L, (12. 83 ± 2. 28) × 10-3 g/L in SA, ACS and control group respectively. There was significant difference within the three groups (F = 11. 544, P ＜ 0. 05). Comparing apoM concentrations among control group and coronary heart disease groups, it showed that the levels of apoM were lower in coronary heart disease groups than in control group(t =2. 962 and 3. 967,P ＜0. 05). There was no significant difference between two coronary heart disease groups (t = 1. 033, P ＞ 0. 05). Conclusion Anti-apoM monoantibodies are successfully raised and could combine with apoM in human cells and tissues. This lays the foundation for the apoM study in apolipoprotein metabolism.     

全外显子组测序鉴定汉族人群扩张型心肌病新的MYH7基因突变

目的：我们应用全外显子测序筛查一个扩张型心肌病患者家系的致病基因。方法：我们对一位在复旦大学附属中山医院就诊的扩张型心肌病患者及其家族成员采集临床资料,同时采集外周血做全外显子测序,寻找可能的致病基因突变,然后用sanger测序对患者及家系成员验证。结果：通过对家系患者及家族成员基因测序分析,经过多个数据库过滤,我们发现了致病基因突变位点MYH7 c.2458G>C (p.Ala820Pro),随后我们发现在家族成员中携带该突变位点的成员心功能异常。检索数据库发现该位点既往未在汉族人群中报道过,首次发现该突变位点与扩张型心肌病有关。结论：本研究通过全外测序发现了一个扩张型心肌病家系的致病基因,为新的汉族人群扩张型心肌病致病位点。     

GLA基因突变致法布雷病家系的三维超声心动图特征分析

目的 应用三维超声心动图（three-dimensional echocardiography，3DE）评估GLA基因突变致法布雷病（Fabry disease，FD）家系的心内膜回声及左室整体纵向收缩功能。方法 纳入2022年10月在复旦大学附属中山医院就诊的8例FD家系成员。采集所有家系成员的2DE及3DE图像，应用TomTec软件分析左室心肌形变参数。结果 8例FD患者中，7例携带GLA突变（NM_000169.2: c.902G＞A，p.Arg301Gln）。GLA基因突变致FD家系成员的心内膜回声增强，其中先证者及其一级亲属（n＝5）心内膜可见“双边征”。患者左室整体纵向收缩功能减弱，表现为整体纵向应变降低。结论 左室整体纵向收缩功能减弱，同时心内膜回声增强提示FD，表明3DE有助于早期诊断FD。     

载脂蛋白M单克隆抗体的制备及其初步应用

Objective To prepare anti-apoM monoantibodies with high affinity and high purity, and investigate apoM distribution among human tissues and different groups of people. Methods BALB/c mice were injected intracutaneously with recombinant apoM. After cytomixis, screening and cloning, we established a hybridoma, which grew well and steadily secreted antibodies. The ascites were acquired by injecting BALB/c mice intraperitoneally and anti-apoM monoantibodies were gained using standard techniques. We detected apoM levels in healthy individuals and the patients with coronary heart disease including stable angina (SA) group and acute coronary syndrome (ACS) group using the anti-apoM monoantibodies. ResultsThree anti-apoM monoantibodies were collected and confirmed after subtype identification and block test. The apoM protein were detected in some human cells and human tissues by these three monoantibodies. The concentration of apoM was (11.02 ±1.96) ×10 -3 g/L, (10. 76± 1.32) ×10-3 g/L, (12. 83 ± 2. 28) × 10-3 g/L in SA, ACS and control group respectively. There was significant difference within the three groups (F = 11. 544, P ＜ 0. 05). Comparing apoM concentrations among control group and coronary heart disease groups, it showed that the levels of apoM were lower in coronary heart disease groups than in control group(t =2. 962 and 3. 967,P ＜0. 05). There was no significant difference between two coronary heart disease groups (t = 1. 033, P ＞ 0. 05). Conclusion Anti-apoM monoantibodies are successfully raised and could combine with apoM in human cells and tissues. This lays the foundation for the apoM study in apolipoprotein metabolism.